628 related articles for article (PubMed ID: 37130601)
21. Meta-Analysis of Clinical Fracture Risk Reduction of Antiosteoporosis Drugs: Direct and Indirect Comparisons and Meta-Regressions.
Albert SG; Wood E
Endocr Pract; 2021 Nov; 27(11):1082-1092. PubMed ID: 34252583
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J).
Huang W; Nagao M; Yonemoto N; Guo S; Tanigawa T; Nishizaki Y
Pharmacoepidemiol Drug Saf; 2023 Jun; 32(6):671-684. PubMed ID: 36703260
[TBL] [Abstract][Full Text] [Related]
23. Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials.
Jin YZ; Lee JH; Xu B; Cho M
BMC Musculoskelet Disord; 2019 Aug; 20(1):399. PubMed ID: 31472671
[TBL] [Abstract][Full Text] [Related]
24. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
25. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
[TBL] [Abstract][Full Text] [Related]
26. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis.
Freemantle N; Cooper C; Diez-Perez A; Gitlin M; Radcliffe H; Shepherd S; Roux C
Osteoporos Int; 2013 Jan; 24(1):209-17. PubMed ID: 22832638
[TBL] [Abstract][Full Text] [Related]
27. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
[TBL] [Abstract][Full Text] [Related]
28. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
29. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.
Yang L; Kang N; Yang JC; Su QJ; Liu YZ; Guan L; Liu T; Meng XL; Wang Y; Hai Y
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2640-2668. PubMed ID: 30964193
[TBL] [Abstract][Full Text] [Related]
30. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
[TBL] [Abstract][Full Text] [Related]
32. Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Viswanathan M; Reddy S; Berkman N; Cullen K; Middleton JC; Nicholson WK; Kahwati LC
JAMA; 2018 Jun; 319(24):2532-2551. PubMed ID: 29946734
[TBL] [Abstract][Full Text] [Related]
33. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
Reginster JY
Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
[TBL] [Abstract][Full Text] [Related]
34. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
Deardorff WJ; Cenzer I; Nguyen B; Lee SJ
JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.
Zhou J; Ma X; Wang T; Zhai S
Osteoporos Int; 2016 Nov; 27(11):3289-3300. PubMed ID: 27273112
[TBL] [Abstract][Full Text] [Related]
36. Romosozumab efficacy and safety in European patients enrolled in the FRAME trial.
Langdahl B; Hofbauer LC; Ferrari S; Wang Z; Fahrleitner-Pammer A; Gielen E; Lakatos P; Czerwinski E; Gimeno EJ; Timoshanko J; Oates M; Libanati C
Osteoporos Int; 2022 Dec; 33(12):2527-2536. PubMed ID: 36173415
[TBL] [Abstract][Full Text] [Related]
37. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.
Scotland G; Waugh N; Royle P; McNamee P; Henderson R; Hollick R
Pharmacoeconomics; 2011 Nov; 29(11):951-61. PubMed ID: 21854080
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials.
Chen L; Wang G; Zheng F; Zhao H; Li H
Osteoporos Int; 2015 Sep; 26(9):2355-63. PubMed ID: 25944731
[TBL] [Abstract][Full Text] [Related]
39. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
